Navigation Links
Treatment Extends Survival in Mouse Model of Spinal Muscular Atrophy

ies that have proven the effectiveness of HDAC inhibitors in humans, she cautions.

The investigators are now testing whether treatment with TSA earlier in the disease process will work better than the delayed treatment in this study. They also plan to test other HDAC inhibitors in mice and to study exactly how the drugs influence the disease process. While TSA is expensive to produce and it is not approved for clinical use, similar drugs being developed to treat cancer and other diseases may be useful for treating SMA, Dr. Sumner says.

Source-Bio-Bio Technology
'"/>




Page: 1 2 3

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...hadrak district now has hopes of pursuing his post...ervened //in his struggle to secure a study loan. ...ed the first position in his graduation in social ...he National Institute of Social Work and Social Sc...
...that by tailoring the intensity of radiation to in...intensive chemotherapy improves outcome for those/...tors led by St. Jude Children’s Research Hospital ...measures for childhood brain cancer medulloblastom...
...s are thought to be inhabited by a rather peculiar... which has peptides attached// together in a patte...nt in the DNA template. This revelation is far rem...e molecular biology textbooks. This discovery ha...
...etic pathway that could help in the eventually hel... The researchers from the Oregon Health & Science ... which demonstrates as to how a genes over-express...o change over from creating hair follicles to crea...
Other Medicine News:Health News:Survival rates improve with better treatment options for medulloblastoma 2Health News:Survival rates improve with better treatment options for medulloblastoma 3Health News:Discovery of A New Genetic Pathway Could Lead To Treatment Of Skin Problems And Cancer 2
(Date:9/3/2008)...results from chronically infected Hepatitis C,pati...ained earlier in 2008, - Study is the first to s... antiviral effect of therapeutic Hepatitis C vac...rt move into a second generation, vaccine formula...gh TLR activation, ...
(Date:9/3/2008)...t. 3 /- Panacea Pharmaceuticals,Inc....r 7,413,737 covering,antibodies against human aspa...rietary human cancer biomarker and therapeutic tar...ion with the Massachusetts Institute of,Technology... to this patent,for development of human cancer di...
(Date:9/3/2008)...ions, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET, SO...stCall/ -- Anesiva,Inc. (Nasdaq: ANSV ) announce...ns to focus on commercial and late-stage product d...alty pharmaceutical pain management,company. The c...
(Date:9/3/2008)... 3 /- A sub-analysis of,the...nt with prasugrel,compared with clopidogrel signif... attacks (7.4 percent vs. 9.7 percent, p<0.0001), ...he time of an artery-opening,procedure known as pe...,occurred spontaneously during the longer-term mai...
Breaking Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6SpectraScience Adds Industry Veteran to Executive Team 21878 1SpectraScience Adds Industry Veteran to Executive Team 21878 2Dont Let Gas Ruin Your Summer BBQ 21876 1Dont Let Gas Ruin Your Summer BBQ 21876 2Cell Therapeutics Inc Repays 2411 0 million Balance of 2008 Convertible Debt 5989 1Cell Therapeutics Inc Repays 2411 0 million Balance of 2008 Convertible Debt 5989 2Fitness a Key Element in Determining Male Diabetics Longevity 21874 1Fitness a Key Element in Determining Male Diabetics Longevity 21874 2
...4 inhibitor, possessing Ki of 27,pM, BOSTON, June ...Inc., a privately held drug discovery biopharmaceu...potent, smart DPP-4 inhibitor,ARI-2243, presented...ciation meeting in Chicago, Illinois. The results ...potent inhibitor of DPP-4 and,produced superior re...
... development of DG041 as an,effective anti-platele... Iceland, June 25, 2007 /PRNewswire-FirstCall/ --,...velopment of,DG041, the company,s Phase II develop...ombosis. The results of the Phase IIa and,clinical...revious,findings demonstrating DG041,s profile as ...
Other Medicine Technology:Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 2Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 3Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 4Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 2Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 3Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 4Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 5Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 6
Surgitie&trade Single Use Ligating Loops without Delivery System with POLYSORB™.
ENDO STITCH&trade Triple-Stitch Single Use Loading Units for use with ENDO Stitch* 10 mm Suturing Device.
ENDO STITCH™ Single Use Loading Units.
...trade; ENDO STITCH™ device is designed for i...d Auto Suture™ trocar sleeves or larger size...he Auto Suture™ ENDO STITCH™ 10 mm sin...DO STITCH™ needle, loaded from a single use ...
Medicine Products: